Monday, October 2, 2023
Monday, October 2, 2023

Contact: 561.316.3330

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

Tampa General Hospital is once again ranked as the #1 hospital in Tampa Bay by U.S. News & World Report for 2021-2022.

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay’s top hospital. Tampa General is also listed among the top four hospitals in Florida and ranked as one of the nation’s top 50 hospitals in five medical specialties, according to the digital media company.

The annual Best Hospitals rankings and ratings, now in their 32nd year, are designed to help patients and their doctors in making informed decisions about where to receive care for challenging health conditions or for common elective procedures. The high U.S. News rankings are a sign of Tampa General’s ability to treat the most complex illnesses and conditions, said TGH President and CEO John Couris.

“Year after year, Tampa General has been recognized as a leading healthcare system by U.S. News & World Report, considered by healthcare consumers as the global leader in quality rankings. Consistency in performance is what is most important as we continue on our journey to become the safest and most innovative academic health system in America,” Couris said. “I’m incredibly proud of our physicians and team members who deliver world-class care to our patients every day. Their dedication and commitment is the reason that Tampa General ranks so highly.”

Tampa General, the primary teaching hospital of the USF Health Morsani College of Medicine and one of the nation’s largest hospitals, is the leading academic medical center on the West Coast of Florida. It is known for performing the most challenging procedures and treating the most complex illnesses.

Tampa General is ranked as one of the nation’s 50 top hospitals, as well as the top hospital in Florida, in these five medical specialties:

  • Ear, Nose & Throat – ranked #21 in U.S. and #1 in Florida
  • Orthopedics – ranked #23 in U.S. and #1 in Florida
  • Gastroenterology & GI Surgery – ranked #26 in U.S. and tied for #1 in Florida
  • Diabetes & Endocrinology – ranked #28 in U.S. and #1 in Florida
  • Rehabilitation – ranked #36 in U.S. and tied for #1 in Florida

Tampa General also ranks as “high performing,” or among the top 10% of U.S. hospitals, in four more specialties:

  • Cancer
  • Geriatrics
  •  Neurology & Neurosurgery
  • Pulmonology & Lung Surgery

Finally, Tampa General also ranks as “high performing” in 12 procedures and conditions that include: Abdominal Aortic Aneurysm Repair, Acute Kidney Failure, COPD, Diabetes, Heart Attack, Heart Bypass Surgery, Heart Failure, Hip Replacement, Knee Replacement, Pneumonia, Spinal Fusion and Stroke.

For the 2021-22 rankings and ratings, U.S. News evaluated more than 4,750 medical centers nationwide in 15 specialties and 17 procedures and conditions. In the 15 specialty areas, 175 hospitals were ranked in at least one specialty. In rankings by state and metro area, U.S. News recognized hospitals as “high performing” across multiple areas of care.

“This year’s expanded report from U.S. News includes new ratings for important procedures and conditions to help each patient pick the right hospital for the type of care they need,” said Ben Harder, managing editor and chief of health analysis at U.S. News. “Hospitals faced incredible challenges this past year, and the best of them have provided great care throughout the pandemic and continue to offer excellent care today.”

The U.S. News Best Hospitals methodologies in most areas of care are based largely on objective measures such as risk-adjusted survival and discharge-to-home rates, volume, and quality of nursing, among other care-related indicators. Best Hospitals was produced by U.S. News with RTI International, a leading research organization based in Research Triangle Park, N.C.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy